##submission.citations##
1. Аляев Ю.Г., Григорян В.А., Чалый М.Е. Нарушения половой и репродуктивной функции у мужчин. — М.: Литтерра, 2006. — 188 с.
2. Каримов Ш.И., Хаджибаев А.М., Хашимов Б.Б. Урология. — Тошкент: Тиб нашриёти, 2010. — 456 б.
3. Лопаткин Н.А. (ред.) Урология: национальное руководство. — М.: ГЭОТАР-Медиа, 2011. — 1024 с.
4. Пушкарь Д.Ю., Раснер П.И. Хронический простатит: диагностика и лечение. — М.: МЕДпресс-информ, 2016. — 96 с.
5. Тиктинский О.Л., Калинина С.Н. Простатиты. — СПб.: Медиа Пресс, 1994. — 320 с.
6. Agarwal A., Virk G., Ong C., du Plessis S.S. Effect of oxidative stress on male reproduction // World J Mens Health. — 2014. — Vol. 32, № 1. — P. 1–17.
7. Anderson R.U., Wise D., Sawyer T. Sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome // J Urol. — 2015. — Vol. 174, № 5. — P. 1748–1751.
8. Bhatt D.L., Bhatt D.L. Inflammation and prostate gland dysfunction: current insights // Eur Urol. — 2017. — Vol. 72, № 4. — P. 534–543.
9. Bhowmick N.A., Chytil A., Bhowmick N.A. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia // Science. — 2004. — Vol. 303. — P. 848–851.
10. Catalona W.J., Partin A.W., Slawin K.M. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease // JAMA. — 2003. — Vol. 279, № 19. — P. 1542–1547.
11. Cornel E.B., Kiemeney L.A., Witjes J.A. The relationship between lower urinary tract symptoms and prostate cancer // World J Urol. — 2014. — Vol. 25, № 6. — P. 597–603.
12. De Marzo A.M., Meeker A.K., Zha S. et al. Human prostate cancer precursors and pathobiology // Urology. — 1999. — Vol. 62, № 5 (Suppl 1). — P. 55–62.
13. Debes J.D., Tindall D.J. The role of androgens and the androgen receptor in prostate cancer // Cancer Lett. — 2002. — Vol. 187, № 1–2. — P. 1–7.
14. Drake R.R., Jones E.E., Powers T.W. et al. Profiling of remaining glycans on formalin-fixed paraffin embedded tissues using mass spectrometry imaging // Anal Chem. — 2018. — Vol. 90, № 14. — P. 8365–8372.
15. Ellem S.J., Risbridger G.P. The dual, opposing roles of estrogen in the prostate // Ann N Y Acad Sci. — 2012. — Vol. 1155. — P. 174–186.
16. Gerstenbluth R.E., Seftel A.D., MacLennan G.T. et al. Distribution of chronic prostatitis in radical prostatectomy specimens // J Urol. — 2002. — Vol. 168, № 6. — P. 2267–2270.
17. John H., Barghorn A., Funke G. et al. Noninflammatory chronic pelvic pain syndrome: immunological study in blood, seminal plasma and prostate tissue // Eur Urol. — 2010. — Vol. 38, № 5. — P. 564–568.
18. Karazanashvili G., Managadze L. Prostate-specific antigen (PSA) value change after antibiotic treatment of prostate inflammation // Eur Urol. — 2001. — Vol. 39, № 4. — P. 483–488.
19. Kramer G., Mitteregger D., Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? // Eur Urol. — 2007. — Vol. 51, № 5. — P. 1202–1216.
20. Lackner J.E., Märk I., Märk R. et al. Bacterial flora in the prostate: important for pathogenesis? // Prostate. — 2006. — Vol. 66, № 4. — P. 430–438.
21. Lowe F.C., Ku J.C. Phytotherapy in treatment of benign prostatic hyperplasia: a critical review // Urology. — 2006. — Vol. 48, № 1. — P. 12–20.
22. Magistro G., Wagenlehner F.M., Grabe M. et al. Contemporary management of chronic prostatitis/chronic pelvic pain syndrome // Eur Urol. — 2016. — Vol. 69, № 2. — P. 286–297.
23. Miyake M., Lawton A., Goodison S. et al. Epigenetic silencing of specific DNA regions in non-muscle invasive and muscle invasive human bladder cancer cells // Int J Cancer. — 2012. — Vol. 130, № 9. — P. 2170–2180.
24. Nelson P.S., Clegg N., Arnold H. et al. The program of androgen-responsive genes in neoplastic prostate epithelium // Proc Natl Acad Sci USA. — 2016. — Vol. 99, № 18. — P. 11890–11895.
25. Nickel J.C., Wagenlehner F.M., Pontari M. et al. Continual improvement in the scientific methodology of CPPS clinical trials // Curr Urol Rep. — 2013. — Vol. 14, № 4. — P. 334–339.
26. Parsons J.K., Nelson C.P., Gage W.R. et al. GSTA1 expression in normal, preneoplastic, and neoplastic human prostate tissue // Prostate. — 2004. — Vol. 49, № 1. — P. 30–37.
27. Perlmutter M.A., Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer // Rev Urol. — 2007. — Vol. 9, Suppl 1. — P. S3–S8.
28. Pontari M.A., Ruggieri M.R. Mechanisms in prostatitis/chronic pelvic pain syndrome // J Urol. — 2004. — Vol. 172, № 3. — P. 839–845.
29. Rees J., Abrahams M., Doble A., Cooper A. Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline // BJU Int. — 2015. — Vol. 116, № 4. — P. 509–525.
30. Sfanos K.S., De Marzo A.M. Prostate cancer and inflammation: the evidence // Histopathology. — 2012. — Vol. 60, № 1. — P. 199–215.
31. Shahed A.R., Shoskes D.A. Oxidative stress in prostatic fluid of patients with chronic pelvic pain syndrome: correlation with gram positive bacterial growth and treatment response // J Androl. — 2001. — Vol. 22, № 4. — P. 532–537.
32. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease // Cell. — 2009. — Vol. 139, № 5. — P. 871–890.
33. Vikram R., Sandler C.M., Ng C.S. Follow-up of benign prostatic hyperplasia: role of imaging // AJR Am J Roentgenol. — 2012. — Vol. 189, № 1. — P. W1–W6.
34. Xue Y., Smedts F., Debruyne F.M. et al. Identification of intermediate cell types by keratin expression in the developing human prostate // Prostate. — 2014. — Vol. 34, № 4. — P. 292–301.